Figure 2

Distribution of the CD14 ^+high CD16 ⁻ , CD14 ^+high CD16 ⁺ and CD14 ^+low CD16 ⁺ monocyte subsets in patients with RA at baseline and over MTX treatment. Panel A shows flow cytometry analysis results for circulating monocytes from a representative responder patient. Percentages of circulating CD14^+highCD16⁻ (panel B), CD14^+highCD16⁺ (panel C) and CD14^+lowCD16⁺ monocytes (panel D) in non-responders (■) and responders (○) at baseline and after 3 and 6 months of MTX treatment, and in healthy controls (▼), are shown as means ± SEM. *Significant difference between patients with RA and healthy controls. ^†Significant difference between non-responders and responders. ^‡Significant difference between baseline and 6 month values.